placebo + boceprevir

placebo + boceprevir refers to a clinical trial intervention arm consisting of an inactive placebo and the hepatitis C virus (HCV) NS3/4A protease inhibitor boceprevir. This combination was specifically utilized in a Phase Ib pharmacokinetic interaction study (NCT01541332) sponsored by Bristol-Myers Squibb to evaluate the safety and drug-drug interaction potential of their investigational compound INX-08189 (BMS-986094) when co-administered with boceprevir. Boceprevir, originally developed by Merck and marketed as Victrelis, is a small molecule alpha-ketoamide that binds reversibly and covalently to the NS3/4A serine protease, thereby inhibiting the processing of the HCV polyprotein and halting viral replication. Boceprevir was approved by the FDA in 2011 for chronic HCV genotype 1 infection but was discontinued in 2015 due to the market dominance of more effective direct-acting antivirals.

Brand names

Victrelis

Other names

placebo + Victrelisplacebo + boceprevir-Bristol-Myers Squibb-hepatitis C